CTOs on the Move


 
Brightseed enables a healthier future by illuminating and activating the connections between people and plants. Despite centuries of wisdom proving the critical roles plants play in supporting our health, the majority of active compounds in the plant kingdom remain unexplored. Our artificial intelligence, Forager®, reveals powerful compounds hidden in nature and our team scientifically validates their impact.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Brightseed raised $27M on 09/15/2020
Brightseed raised $68M on 05/09/2022

Similar Companies

Styker Biotech

Styker Biotech is a West Lebanon, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AgriMetis

AgriMetis discovers, develops, and delivers innovative crop protection products. Our scientific approach is multidisciplinary and integrated which allows AgriMetis to exploit areas of chemical space and production routes that are inaccessible to others. The AgriMetis platform delivers rapid, efficient, and optimal solutions to challenges in crop protection by bringing innovative products and their production processes to the market faster for the $56 billion agricultural chemical industry.

Barc USA

Barc USA is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cartography Biosciences

Cartography Biosciences is focused on developing tumor-selective therapeutics that are based on a unique genomics and computational platform. Cartography`s platform integrates data from proprietary sample sourcing relationships, an industry-leading comprehensive reference atlas, and our target identification algorithms to identify the cells of interest and the single or pairs of targets that are most specific to the intended target cells. Cartography is unlocking the full potential of immunotherapy by discovering and developing therapeutics as precise as their targets. To learn more about Cartography and our mission to treat every patient with cancer.

Avectas

Avectas is a cell engineering technology business developing a unique delivery platform to enable the ex vivo manufacture of gene-modified cell therapy products, which will retain high in vivo functionality. Our vision is to position the non-viral SOLUPORE® cell engineering technology to be integrated into manufacturing processes for multiple autologous and allogeneic therapies and commercialised through development and license agreements.